ABT-199 (venetoclax) is a potent, specific BCL-2 inhibitor that does not inhibit other anti-apoptotic molecules and avoids the thrombocytopenia associated with inhibition of BCL-XL [18]. Here, BCL2 is linked to Thrombocytopenia.